Dienogest reduces endometrioma volume and endometriosis-related pain symptoms


Uludag S. Z. , Demirtas E. , Sahin Y., AYGEN E. M.

JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası:
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1080/01443615.2020.1867962
  • Dergi Adı: JOURNAL OF OBSTETRICS AND GYNAECOLOGY

Özet

This study aimed to evaluate the efficacy and adverse effects of dienogest for the treatment of endometriomas. Dienogest (2 mg/day) was administered to patients with endometrioma continuously through the 6-month study period. The patients were prospectively examined on the efficacy and side effects at baseline, at third months, and sixth months of the treatment. Twenty-four out of 30 patients were able to complete the study. The mean volume of the endometrioma decreased significantly from 112.63 +/- 161.31 cm(3) at baseline to 65.47 +/- 95.69 cm(3) at a 6-month follow-up (-41%) (p = .005). The VAS score for pelvic pain decreased significantly from 7.50 to 3.00 (p < .001) at the sixth months of treatment. The most common side effects were menstrual irregularities. Laboratory parameters did not change during the study. Dienogest considered being effective for 6 months of use in decreasing the size of endometrioma, reducing endometriosis-associated pain with a favourable safety and tolerability profile. Impact statement